

LITERATURA

- Kanwal F, Neuschwander-Tetri BA, Loomba R, et al. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. *Hepatology*. 2024;79(5):1212-1219.
- Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. *Diabetes Care*. 2025 Jul 1;48(7):1057-1082.
- European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J Hepatol*. 2024;81(3):492-542.
- Verdecchia P, Murdolo G, Coiro S, et al. Therapy of Type 2 diabetes: more gliflozins and less metformin? *Eur Heart J Suppl*. 2023;25(Suppl B):B171-B176.
- Tilg H, Petta S, Stefan N, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review. *JAMA*. 2026 Jan 13;335(2):163-174.
- Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol*. 2015;13:643-54.e1-9; quiz e39-40.
- Li D, Zhang X. From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma. *Hepatol Commun*. 2025 Dec 1;9(12):e0846.
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023;77:1797-1835.
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology*. 2015;149(2):367-378.e5.
- Dey P. The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what's different? *Front Endocrinol (Lausanne)*. 2025 Oct 20;16:1693123.
- Zhang X, Lau HC, Yu J. Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options. *Pharmacol Rev*. 2025;77(2):100018.
- Fouad Y, Mostafa AM, Gomaa A, et al. Lean MASH: A High-Risk Subtype With Significant Cardiometabolic Burden. *J Gastroenterol Hepatol*. 2026 Feb;41(2):817-818.
- Trifan A, Rotaru A, Stafie R, et al. Clinical and laboratory characteristics of normal weight and obese individuals with nonalcoholic fatty liver disease. *Diagnostics (Basel)*. 2022;12(4):801.
- Njei B, Boateng S, Mohamed M, et al. Lean MASLD in U.S. Adults: Undiagnosed Burden and Metabolic Features from NHANES 2017-2020. *J Gen Intern Med*. 2025 Dec 16. doi:10.1007/s11606-025-10086-8.
- Wu S. Reconciling Definitions, Phenotypes and Outcomes in Lean MASLD: Editorial on „Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations“. *Clin Mol Hepatol*. Published online January 27, 2026. doi:10.3350/cmh.2026.0004.
- Song SJ, Yoon EL, Wong VW, et al. Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations. *Clin Mol Hepatol*. Published online December 12, 2025. doi:10.3350/cmh.2025.0851.
- Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2020;5:739-52.
- Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol*. 2018;15:11-20.
- Chen M, Cao Y, Ji G, Zhang L. Lean nonalcoholic fatty liver disease and sarcopenia. *Front Endocrinol*. 2023;14:1217249.
- Lu C-W, Chou T-J, Wu T-Y, et al. PNPLA3 and SAMM50 variants are associated with lean nonalcoholic fatty liver disease in Asian population. *Ann Hepatol*. 2025;30:101761.
- Bhattacharya I, Maity DK, Kumar A, et al. Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement. *Naunyn Schmiedebergs Arch Pharmacol*. 2025;398(10):13647-13665.
- Sharma B, John S. Nonalcoholic Steatohepatitis (NASH)(Archived). In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; April 7, 2023.
- Younossi ZM, Henry L. Understanding the burden of nonalcoholic fatty liver disease: time for action. *Diabetes Spectr*. 2024;37:9-19.
- Bianco A, Bonfiglio C, Franco I, et al. Sedentary Behavior as a Risk Factor for Liver Fibrosis Development in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Cross-Sectional Study. *J Clin Med*. 2025 Oct 24;14(21):7553.
- Gunn NT. Lean nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. *Gastroenterol Hepatol (N Y)*. 2021;17:184-6.
- Sato-Espinoza K, Chotiprasidhi P, Huaman MR, et al. Update in lean metabolic dysfunction-associated steatotic liver disease. *World J Hepatol*. 2024;16:452-64.
- Huo Z, Chen Y, Huang Y, et al. Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts. *Gut*. 2025 Oct 15;gutjnl-2025-336127.
- Dhruv S, Ginnaram S, Fonkam A, et al. Predictors of Development of Hepatocellular Carcinoma in Non-Cirrhotic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis – A Retrospective Analysis of the National Inpatient Sample Database. *Gastroenterology Res*. 2025 Aug 7;18(5):224-231.
- Sanyal AJ, Newsome P N, Kliersl, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. *N Engl J Med*. 2025;392(21):2089-2099.
- Sanyal AJ, Chalasani N, Kowdley KV, et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med*. 2010 May 6;362(18):1675-85.
- Ito D, Shimizu S, Haisa A, et al. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD. *J Diabetes Investig*. 2024 Sep;15(9):1220-1230.

Pro věrné čtenáře

Součástí tohoto čísla *Vnitřní lékařství* je navíc supplementum **Zaznělo na 21. interní medicíně pro praxi**, které přináší přehledná shrnutí vybraných bloků z jarního kongresu *Interní medicína pro praxi* v Olomouci.

Čtenáři v něm najdou prakticky zaměřené texty věnované například rizikům glukokortikoidy indukované osteoporózy, specifickým léčby hypertenze u pacientů s obezitou a chronickým onemocněním ledvin, diagnostice a terapii primární biliární cholangitidy, možností využití atypického anxiolytika či zkušenostem s léčbou mavakamtenem.

Supplementum tak připomíná aktuální internistická témata s důrazem na jejich využití v každodenní ambulanci i nemocniční praxi. Věříme, že pro vás návrat k této významné odborné akci bude přínosný a inspirativní.

